London has long been a global hub for innovation, and its prominence in the life sciences sector has been reaffirmed with its recognition as a key industry in the recently announced London Growth Plan. This strategic blueprint, designed to drive economic expansion and job creation, highlights life sciences as a fundamental pillar for the city’s…
A new study from Queen Mary University of London found that 9% of all adverse drug reactions (ADRs) reported to the UK medicines regulator are associated with medications where side effect risk is partly dependent on patient’s genes. Of this subset of ADRs, 75% were associated with only three genes that impact how the body processes medication. Genetic testing before prescribing could therefore help…
Queen Mary BioEnterprises Innovation Centre has teamed up with Lateral and HIG to run its new incubator hub. The 37,000 sq. ft. facility will be part of a larger redevelopment project at 100-136 Cavell Street, E1. This exciting initiative is set to transform a former clothing factory into a cutting-edge life sciences facility, with a…
Location: Queen Mary Innovation Centre, 5 Walden Street, London, E1 2EF Supported by: Hume Brophy Date: 14th April Time: 14.00 – 19.30
Immuno-Oncology (IO) has been one of, if not the, hottest area in biopharma over recent years. High profile financings, approvals and challenges have emerged and competition for new innovative programmes is fierce.
Location: Queen Mary Innovation Centre, 5 Walden Street, London, E1 2EF Date: 13th February Time: 14.00 – 19.30